| 景强强,姚龙.冠心病患者PCI围手术期双倍剂量阿托伐他汀干预的效果及安全性分析.[J].中南医学科学杂志.,2016,(5):544-547. |
| 冠心病患者PCI围手术期双倍剂量阿托伐他汀干预的效果及安全性分析 |
| Analysis of the Effects and Safety of Double-Doses Atorvastatin Intervention in Patients with CAHD During Perioperative Period of PCI |
| 投稿时间：2016-01-22 修订日期：2016-04-28 |
| DOI： |
| 中文关键词: 冠状动脉粥样硬化性心脏病 阿托伐他汀 不同剂量 围手术期 |
| 英文关键词:coronary atherosclerotic heart disease atorvastatin different dose perioperative period |
| 基金项目: |
|
| 摘要点击次数: 946 |
| 全文下载次数: 703 |
| 中文摘要: |
| 目的 探讨双倍剂量阿托伐他汀在冠心病患者围手术期的应用效果及安全性。方法经本院伦理学委员会批准,以本院2013年2月～2015年6月择期行经皮冠状动脉介入术(PCI)的86例冠心病患者为研究对象,随机数字表格法将其分为观察组与对照组,所有患者PCI围手术期均给予阿托伐他汀干预,观察组阿托伐他汀用药剂量40 mg/天,对照组用药剂量20 mg/天,术后平均随访6个月,比较两组疗效及安全性。结果观察组术后6个月TC、TG、LDL-C水平均明显低于对照组(P＜0.05)。观察组术后1周CK-MB、cTn-I水平分别为(13.30±4.05)U/L、(0.03±0.03)μg/L,均显著低于对照组的(17.73±5.15)U/L、(0.10±0.09)μg/L,差异有统计学意义(P＜0.05)。对照组手术前后hs-CRP水平比较差异显著(P＜0.05),而观察组无显著差异(P＞0.05)。两组药物不良反应发生率比较无显著差异(P＞0.05)。术后6个月,观察组支架内再狭窄、心肌梗死发生率分别为9.3%、2.3%,均显著低于对照组的27.9%、14.0%(P＜0.05)。结论冠心病患者围手术期应用双倍剂量阿托伐他汀相比常规剂量对PCI术后心肌损伤保护作用更明显,能显著降低支架内再狭窄、心肌梗死发生率,且不增加药物不良反应,安全性较高。 |
| 英文摘要: |
| Objective To investigate the application effect and safety of double-dose atorvastatin in patients with coronary atherosclerotic heart disease (CAHD) during perioperative period.Methods86 patients with CAHD treated by percutaneous coronary intervention (PCI) in our hospital from February 2013 to June 2015 were selected as the study objects and were divided into observation and control groups.All patients were given atorvastatin intervention during perioperative period of PCI.The dosage of atorvastatin in the observation group was 40 mg/day while in the control group was 20 mg/day.After operation,they were followed up for about 6 months.The curative effect and safety of the two groups were compared.Results6 months after operation,the levels of TC,TG and LDL-C in the observation group were significantly lower than those in the control group.(P<0.05).1 week after operation,the levels of CK-MB and cTn-I in observation group [(13.30±4.05) U/L,(0.03±0.03) μg/L] were significantly lower than those in the control group [(17.73±5.15) U/L,(0.10±0.09) μg/L](P<0.05).The difference in hs-CRP levels before and after operation in the control group were significant (P<0.05) but there was no significant difference in the observation group (P>0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups (P>0.05).Six months after operation,the incidence rates of in-stent restenosis and myocardial infarction in the observation group (9.3%,2.3%) were significantly lower than those in the control group (27.9%,14.0%) (P<0.05).ConclusionsThe protective effect of double-dose atorvastatin to myocardial injury in patients with CAHD during perioperative period after PCI is more obvious than that of routine dose.It can significantly reduce the incidence of in-stent restenosis and myocardial infarction and does not increase adverse drug reactions,with high safety. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|